Publications by authors named "Rachel Totoritis"

Claim this Profile
I
Identification of Diarylurea Inhibitors of the Cardiac-Specific Kinase TNNI3K by Designing Selectivity Against VEGFR2, p38α, and B-Raf.
Jaclyn R Patterson, Alan P Graves, Patrick Stoy, Mui Cheung, Tina A Desai, Rachel Totoritis

J Med Chem· November 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Characterization of Apo-Form Selective Inhibition of Indoleamine 2,3-Dioxygenase*.
Rodrigo F Ortiz-Meoz, Liping Wang, Rosalie Matico, Anna Rutkowska-Klute, Martha De la Rosa, Rachel Totoritis

Chembiochem· February 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Correction to Identification of Quinoline-Based RIP2 Kinase Inhibitors with an Improved Therapeutic Index to the hERG Ion Channel.
Pamela A Haile, Linda N Casillas, Michael J Bury, John F Mehlmann, Robert Singhaus, Rachel D Totoritis

ACS Med Chem Lett· June 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Modular Protein Ligation: A New Paradigm as a Reagent Platform for Pre-Clinical Drug Discovery.
Rosalie Matico, Lawrence M Szewczuk, Beth Pietrak, Stephanie Chen, Ed Dul, Rachel Totoritis

Sci Rep· September 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Identification of a RIP1 Kinase Inhibitor Clinical Candidate (GSK3145095) for the Treatment of Pancreatic Cancer.
Philip A Harris, Jill M Marinis, John D Lich, Scott B Berger, Anirudh Chirala, Rachel D Totoritis

ACS Med Chem Lett· June 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery and Lead-Optimization of 4,5-Dihydropyrazoles as Mono-Kinase Selective, Orally Bioavailable and Efficacious Inhibitors of Receptor Interacting Protein 1 (RIP1) Kinase.
Philip A Harris, Nicolas Faucher, Nicolas George, Patrick M Eidam, Bryan W King, Rachel D Totoritis

J Med Chem· May 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Identification of Quinoline-Based RIP2 Kinase Inhibitors with an Improved Therapeutic Index to the hERG Ion Channel.
Pamela A Haile, Linda N Casillas, Michael J Bury, John F Mehlmann, Robert Singhaus, Rachel D Totoritis

ACS Med Chem Lett· October 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of a First-in-Class Receptor Interacting Protein 1 (RIP1) Kinase Specific Clinical Candidate (GSK2982772) for the Treatment of Inflammatory Diseases.
Philip A Harris, Scott B Berger, Jae U Jeong, Rakesh Nagilla, Deepak Bandyopadhyay, Rachel D Totoritis

J Med Chem· February 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Identification and Pharmacological Characterization of 6-(tert-Butylsulfonyl)-N-(5-fluoro-1H-indazol-3-yl)quinolin-4-amine (GSK583), a Highly Potent and Selective Inhibitor of RIP2 Kinase.
Pamela A Haile, Bartholomew J Votta, Robert W Marquis, Michael J Bury, John F Mehlmann, Rachel D Totoritis

J Med Chem· May 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
DNA-Encoded Library Screening Identifies Benzo[b][1,4]oxazepin-4-ones as Highly Potent and Monoselective Receptor Interacting Protein 1 Kinase Inhibitors.
Philip A Harris, Bryan W King, Deepak Bandyopadhyay, Scott B Berger, Nino Campobasso, Rachel D Totoritis

J Med Chem· March 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-Range Inhibitor-Induced Conformational Regulation of Human IRE1α Endoribonuclease Activity.
Nestor O Concha, Angela Smallwood, William Bonnette, Rachel Totoritis, Guofeng Zhang

Mol Pharmacol· December 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Crystal structures of human RIP2 kinase catalytic domain complexed with ATP-competitive inhibitors: Foundations for understanding inhibitor selectivity.
Adam K Charnley, Máire A Convery, Ami Lakdawala Shah, Emma Jones, Philip Hardwicke, Rachel Totoritis

Bioorg Med Chem· November 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Identification of Purines and 7-Deazapurines as Potent and Selective Type I Inhibitors of Troponin I-Interacting Kinase (TNNI3K).
Brian G Lawhorn, Joanne Philp, Yongdong Zhao, Christopher Louer, Marlys Hammond, Rachel Totoritis

J Med Chem· September 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A human fatty acid synthase inhibitor binds β-ketoacyl reductase in the keto-substrate site.
Mary Ann Hardwicke, Alan R Rendina, Shawn P Williams, Michael L Moore, Liping Wang, Rachel D Totoritis

Nat Chem Biol· September 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of Small Molecule RIP1 Kinase Inhibitors for the Treatment of Pathologies Associated with Necroptosis.
Philip A Harris, Deepak Bandyopadhyay, Scott B Berger, Nino Campobasso, Carol A Capriotti, Rachel D Totoritis

ACS Med Chem Lett· December 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Understanding the origins of time-dependent inhibition by polypeptide deformylase inhibitors.
Rachel Totoritis, Chaya Duraiswami, Amy N Taylor, John J Kerrigan, Nino Campobasso

Biochemistry· August 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evaluation of an antibody-free ADP detection assay: ADP-Glo.
Hu Li, Rachel D Totoritis, Leng A Lor, Benjamin Schwartz, Peter Caprioli

Assay Drug Dev Technol· December 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis